LifePoint soars on FDA medical markets nod
This article was originally published in Clinica
Executive Summary
LifePoint saw is stock price surge last week, after revealing that the US FDA has given it the all-clear to expand sales of its saliva-based, on-site test system for detecting the opiates morphine and heroin to medical markets. The firm's shares rose around 40% during trading on Dec 1 when the news was announced.